SHR-1210 + Apatinib + Sorafenib
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced or Metastatic and Unresectable HCC
Conditions
Locally Advanced or Metastatic and Unresectable HCC
Trial Timeline
Jun 10, 2019 → Jun 14, 2023
NCT ID
NCT03764293About SHR-1210 + Apatinib + Sorafenib
SHR-1210 + Apatinib + Sorafenib is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Locally Advanced or Metastatic and Unresectable HCC. The current trial status is completed. This product is registered under clinical trial identifier NCT03764293. Target conditions include Locally Advanced or Metastatic and Unresectable HCC.
What happened to similar drugs?
5 of 20 similar drugs in Locally Advanced or Metastatic and Unresectable HCC were approved
Approved (5) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03764293 | Phase 3 | Completed |
Competing Products
20 competing products in Locally Advanced or Metastatic and Unresectable HCC